Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides siboney allergen vaccine + neisseria meningitidis b proteoliposome adjuvant
- Development stage
- Unknown
- Lead developer
- BioCen
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A therapeutic allergen vaccine developed by Centro Nacional de Biopreparados (BioCen) for the treatment of allergic asthma in mite-sensitized patients. It consists of an allergen extract from the house dust mite *Dermatophagoides siboney* formulated with a proteoliposome adjuvant derived from *Neisseria meningitidis* serogroup B. The adjuvant, which contains outer membrane vesicles (OMVs), is designed to enhance immune modulation by shifting the allergic Th2-driven response toward a Th1 or regulatory T-cell (Treg) profile, thereby increasing clinical tolerance to the allergen. It is currently in Phase 2 clinical development.
- Brand names
- PROLINEM-DS
- Other names
- Dermatophagoides siboney + proteolipsome adjuvantVALERGEN-DS + OMV adjuvant
02
Targets
Der s (Dermatophagoides siboney allergen)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on dermatophagoides siboney allergen vaccine + neisseria meningitidis b proteoliposome adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides siboney allergen vaccine + neisseria meningitidis b proteoliposome adjuvant.